Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Carcinoma, Medullary × Ranitidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2 Prostatic Neoplasms 1 Neoplasms 1 Kidney Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Medullary 1 Breast Carcinoma In Situ 1 Brain Neoplasms 1 Advanced Cancer 1

Interventions

vandetanib 9 Everolimus 4 sargramostim 2 cabozantinib 2 Trastuzumab 2 Sunitinib 2 Sorafenib 2 Gefitinib 2 yeast-CEA vaccine 1 vatalanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tipifarnib 1 temsirolimus 1 tanespimycin 1 sacubitril and valsartan sodium hydrate drug combination 1 pralsetinib 1 pembrolizumab 1 pazopanib 1 pasireotide 1 nintedanib 1 motesanib diphosphate 1 mercaptoundecahydrododecaborate 1 lenvatinib 1 fluorodopa F 18 1 cixutumumab 1 anlotinib 1 aldesleukin 1 Vorinostat 1 Vinorelbine 1 Thalidomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01539655 2017-05-02

Vandetanib

Sanofi

Phase 1 Completed

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡